Paratek Pharmaceuticals Inc. (PRTK)

Business: Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.

IPO Date: 11-May-2006

Exec. Chairman: Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA

CEO & Director: Dr. Evan Loh FACC, FAHA, M.D.

Listing: NASDAQ: PRTK

Country: United States

Headquarters: Boston, MA

Website: https://paratekpharma.com

Market cap: $112.23 Mln

Revenue (TTM): $136.50 Mln

Earnings (TTM): $-58.65 Mln

Cash: $79.05 Mln

Total Debt: $257.01 Mln

Insider's Holding: 16.58%

Liquidity: Low

52 Week range: $1.60 - 7.27

Shares outstanding: 54,478,500

10 Years Aggregate:

• CFO: $-642.83 Mln
• EBITDA: $-633.53 Mln
• Net Profit: $-725.63 Mln